Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX01 plus CHOP vs Rituximab plus CHOP in untreated diffuse large B‑cell lymphoma
CTR20150583Phase 3Completed
- Sponsor
- Henlius
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Henlius. Started Aug 2015; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20150583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150583.